SCHEMBL5485914

SCHEMBL5485914

O=C(CCSSc1ccccn1)ON1C(=O)CC(S(=O)(=O)O)C1=O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
HDAC1 Q13547 7/20 0.33
HDAC4 P56524 5/20 0.33
HDAC6 Q9UBN7 3/20 0.33
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
HDAC2 Q92769 2/20 0.32
LMNA P02545 2/20 0.32
ELANE P08246 2/20 0.31
HSD17B10 Q99714 1/20 0.31
EHMT2 Q96KQ7 1/20 0.31
EHMT1 Q9H9B1 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30367749 1.00 ALDH1A1 (0.36) ALDH1A1HDAC1HDAC4HDAC6MAPT
SCHEMBL16047481 0.94 HDAC1 (0.36) ALDH1A1HDAC1HDAC4HDAC6HDAC2
SCHEMBL5051961 0.93 HDAC1 (0.33) ALDH1A1HDAC1HDAC4HDAC6HDAC2
SCHEMBL2033142 0.90 ALDH1A1 (0.45) ALDH1A1MAPTKMT2APOLBLMNA
SCHEMBL44111 0.89 HPGD (0.37) ALDH1A1HDAC1HDAC4HDAC6MAPT
SCHEMBL29361373 0.89 HPGD (0.37) ALDH1A1HDAC1HDAC4HDAC6MAPT
SCHEMBL19713428 0.86 HPGD (0.35) HDAC1HDAC4HDAC6HDAC2LMNA
SCHEMBL5499529 0.86 ALDH1A1 (0.39) ALDH1A1HDAC1HDAC4HDAC6MAPT
SCHEMBL12056750 0.85 HPGD (0.36) HDAC1HDAC4HDAC6HDAC2
SCHEMBL7200996 0.85 POLB (0.34) ALDH1A1MAPTKMT2APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499712-A2 TARGETED DELIVERY Judo Bio Inc. (US) 2025-02-05 EP disclosed
CN-113039191-B Nucleotide analogues 奇异基因组学系统公司 2024-07-16 CN disclosed
WO-2023183628-A9 TARGETED DELIVERY JUDO BIO INC. (US) 2023-11-30 WO disclosed
WO-2023183628-A2 TARGETED DELIVERY JUDO BIO INC. (US) 2023-09-28 WO disclosed
US-20100273724-A1 PEGYLATED ION CHANNEL MODULATING COMPOUNDS CARDIOME PHARMA CORP. (CA) 2010-10-28 US disclosed
US-7786119-B2 Drug conjugates of ion channel modulating compounds CARDIOME PHARMA CORP. (CA) 2010-08-31 US disclosed
US-20080021005-A1 Pegylated Ion Channel Modulating Compounds CARDIOME PHARMA CORP. (CA) 2008-01-24 US disclosed
US-7238799-B2 Mustang, a gene and nuclear protein RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT STONY BROOK (US) 2007-07-03 US disclosed
US-20050164206-A1 Mustang, a novel gene and nuclear protein THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2005-07-28 US disclosed
EP-0941738-B1 Antigenic conjugates of conserved lipooligosaccharides of gram negative bacteria WYETH CORP (US) 2005-05-11 EP disclosed
US-20040248081-A1 LANA viral protein binding sites THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2004-12-09 US disclosed
US-20040052804-A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria WYETH HOLDINGS CORPORATION 2004-03-18 US disclosed
US-6645503-B1 Eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria; vaccines; comprises the inner core and lipid A portions of the lipopolysaccharide WYETH HOLDINGS CORPORATION 2003-11-11 US disclosed
US-20030133948-A1 Methods to inhibit or enhance the binding of viral DNA to genomic host DNA THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2003-07-17 US disclosed
US-6482587-B1 Methods to inhibit or enhance the binding of viral DNA to genomic host DNA THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2002-11-19 US disclosed
WO-2001025484-A2 METHODS TO INHIBIT OR ENHANCE THE BINDING OF VIRAL DNA TO GENOMIC HOST DNA THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2001-04-12 WO disclosed
US-6200801-B1 A POLYCATION AND A BINDING MOIETY OF DEFINED AMINO ACID SEQUENCE CAPABLE OF BINDING TO A SERPIN ENZYME COMPLEX RECEPTOR FOR TARGETED GENE DELIVERY; GENE THERAPY; ANTISENSE AGENTS CASE WESTERN RESERVE UNIVERSITY 2001-03-13 US disclosed
US-5972901-A MAKING A COMPOSITION FOR DELIVERING AN OLIGONUCLEOTIDE TO A MAMMALIAN CELL BY PROVIDING A PEPTIDE TARGET BINDING MOIETY BEING CAPABLE OF BINDING TO A SERPIN ENZYME COMPLEX RECEPTOR, POLYLYSINE, AN OLIGONUCLEOTIDE VECTOR; CONJUGATING, COUPLING CASE WESTERN RESERVE UNIVERSITY (US) 1999-10-26 US disclosed
EP-0941738-A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria American Cyanamid Company (US) 1999-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021005-A1 Pegylated Ion Channel Modulating Compounds KCNN3, KCNN2, KCNN1 ALDH1A1 2835/4885HDAC1 1767/4885HDAC4 1653/4885
US-20100273724-A1 PEGYLATED ION CHANNEL MODULATING COMPOUNDS KCNN3, KCNN2, KCNN1 ALDH1A1 2835/4885HDAC1 1767/4885HDAC4 1653/4885
US-20040052804-A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria LY96, DDOST, LRBA ALDH1A1 4023/4885HDAC1 2949/4885HDAC4 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.